The settlement requires that Curiox refrain from saying that one of its products has equivalent or better sensitivity and reproducibility than a Luminex system.
The assay is part of a respiratory testing menu that includes assays for Bordetella and Flu A/B & RSV, and NxTAG and Verigene respiratory pathogen panels.
Luminex said that its total sample-to-answer molecular product revenue of $11.9 million grew 55 percent from $7.7 million in the third quarter of 2016.
The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today.
Luminex alleges that Curiox's objective has been to cobble together an unvalidated "Frankenstein-ish" system that fails at producing accurate test results.
The firm said that prior to entering clinical trials, it also needs to reduce failure rates of a cassette that is part of the Verigene 2 test.
The firm said that it is delaying clinical trials prior to its FDA submission of Verigene 2 for several reasons, including reducing cassette failure rates.
The fourth test for which the firm has received regulatory clearance this year takes aim at a common microbial cause of healthcare-associated infections.
The firm's real-time PCR assay for rapid detection and differentiation of novovirus genogroup I and II runs on the Aries sample-to-answer system.
The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.